The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.
 
Kathleen N. Moore
Consulting or Advisory Role - Advaxis; AstraZeneca (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunogen (Inst); TESARO (Inst); VBL Therapeutics (Inst)
Travel, Accommodations, Expenses - Novocure; Takeda Milenium
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Biogen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Fresenius (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hampton Medical Conferences (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Kendle (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Quintiles (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst); Sigma-Tau (Inst); Telik (Inst); TRM Oncology (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Proacta (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche
 
Ana Oaknin
No Relationships to Disclose
 
Nicoletta Colombo
Employment - Ignyta (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; MSD Oncology; Pfizer; PharmaMar; Roche/Genentech
 
Susana N. Banerjee
Consulting or Advisory Role - AstraZeneca (Inst); Clovis Oncology (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology
 
Amit M. Oza
Honoraria - WebRx
Consulting or Advisory Role - Amgen; Clovis Oncology; Immunovaccine; Verastem
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Merck (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Patricia Pautier
No Relationships to Disclose
 
Catherine Margaret Kelly
No Relationships to Disclose
 
Karim S. Malek
Employment - ImmunoGen
 
Rodrigo Ruiz-Soto
Employment - ImmunoGen
 
Michael J. Birrer
Consulting or Advisory Role - Acceleron Pharma; Merrimack; Oxigene; Roche/Genentech; Sanofi; Threshold Pharmaceuticals